Refine by
Drugs For The Treatment Articles & Analysis
136 news found
(Huateng Pharma), a global leader in the development and production of high-quality PEG derivatives, is pleased to announce that its mPEG-pALD (20K) has successfully completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA), under DMF No. 040600. ...
Profacgen, a leading provider of custom biotechnology services, is pleased to announce significant updates to its Antimicrobial Peptides (AMPs) Services, enhancing its capabilities to support the growing demand for alternative therapies in the fight against drug-resistant pathogens. As antibiotic resistance continues to pose a global health threat, Profacgen is expanding its ...
To help pharmaceutical partners and academic institutions overcome the challenges of low bioavailability and unsustainable drug release in drug formations for glaucoma, Ace Therapeutics is proud to announce the unveiling of its cutting-edge drug delivery system development services for the treatment of glaucoma. ...
This service is particularly valuable for developing treatments for drug-resistant bacterial infections, a growing concern in both healthcare and veterinary settings. ...
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. ...
Shanghai and Hong Kong, PRC, December 23, 2022 — Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug ...
In the study, DS predicted HMA response in MDS patients and showed a strong correlation to the treatment efficacy score (ES). Non-responders had lower DS and survival than patients with high DS. ...
LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been designated as an orphan drug by the US FDA. On December 1, 2022, the US FDA notified LISCure of the orphan drug designation of LB-P8, LISCure's microbiome novel drug, as ...
No hematological safety signal was observed and none of the patients in either of the two treatment arms had sinus bradycardia. Virginia Kaklamani, MD, DSc, breast medical oncologist and professor of medicine, UT Health San Antonio, MD Anderson Cancer Center, commented, “These results show that when used as a single agent, elacestrant provided mPFS up to 8.6 months, based ...
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a Cellworks biosimulation pilot study, which examined the impact of mismatch repair deficiency (MRD) on survival of temozolomide (TMZ)-treated patients with MGMT methylated (m-MGMT) glioblastoma (GBM). ...
Creative BioMart, a biotechnology company that offers a wide range of solutions dedicated to helping researchers and pharmaceutical companies discover and develop novel drugs in the treatment of cancer, autoimmune diseases, etc., now offers MHC solutions for cell therapy and vaccine development. ...
Through these products, we unlock the hidden value of data, accelerate novel drug and treatment discovery and ensure better and proactive patient engagement. ...
“Our initial focus will be on the treatment of lower respiratory tract infections, for which there remains a significant unmet need. Our differentiated device technology platform has the potential to simplify the delivery of higher efficiency inhalation drug products, making effective therapies available for patients with compromised lung function.” ...
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox. In recent weeks, randomized, placebo-controlled clinical trials were initiated in ...
“Based on strong preclinical and emerging clinical data, we believe there is good synergy between PD-1 and LILRB antagonists for the treatment of solid tumors. We look forward to working with Immune-Onc to explore the possibility of combination therapy with our products, which may bring more treatment options to cancer patients in ...
The compound is also being developed by Enalare for the treatment of post-operative respiratory depression and community drug overdose. Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening critical care conditions and community based health emergencies, announced today that ...
Refractory epilepsy, referred to as uncontrolled, intractable, or drug-resistant epilepsy, occurs when medications do not bring seizures under control. Epilepsy patients that are refractory to oral anti-epileptic drug treatment have significantly higher mortality, higher morbidity, higher economic costs and diminished quality of life compared to ...
This Award seeks to recognize success in a clinical trial of a new drug product (biological or chemical) that is expected to lead to an advance in healthcare. ...
Bvlaser is a CO2 fractional laser machine factory supplier, we have fractional CO2 laser for skin rejuvenation. CO2 laser treatment for acne scars With the development of medical conditions, there are more and more treatment methods for acne marks, and the development of laser technology is also very rapid. ...
As the leading expert in computer-aided drug discovery, BOC Sciences has developed compound docking technologies to facilitate the discovery of novel ligands for over 30 targets. ...